EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification and characterization of novel chikungunya virus polymerase inhibitors

Peiqi Yin iD, Ryan Boyce, Sainan Wang, Michael Sirrine, Alexander Leach, Dillon Chu, Dariia Vyshenska, Zafer Sahin, Jenny Wong, Tahirah Moore, Devin Shane M Lewis, Stephen C Pelly und 6 weitere

Journal of Virology · 23.06.2026 · 100 (6)

DOI: 10.1128/jvi.00305-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 23.06.2026. Verfasst von Peiqi Yin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Chikungunya virus, Antiviral Agents, RNA-Dependent RNA Polymerase, Enzyme Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chikungunya virus (CHIKV) and other alphaviruses in the Togaviridae family are positive-sense RNA viruses and major human pathogens, causing millions of infections worldwide. In humans, alphaviruses, such as CHIKV, Mayaro, and Ross River viruses, typically cause arthritogenic disease characterized by debilitating arthralgia, joint inflammation, fever, and rash. Although a vaccine was recently approved for use against CHIKV, no vaccines are licensed against other alphaviruses. No antiviral treatments are available to prevent or treat infections by any alphavirus. To address this unmet need, we used a CHIKV nanoluciferase reporter virus to develop a high-throughput screening assay for novel small-molecule inhibitors. From this campaign, we identified several unique inhibitors of CHIKV replication. Mechanistic characterization of two inhibitors suggests that both target the nsP4 RNA-dependent RNA polymerase. Susceptibility profiling pinpointed unique nsP4 mutations that specifically conferred resistance but also decreased viral fitness in competition studies. In silico docking and resistance profiling analyses indicated potential binding sites of the inhibitors near the polymerase active site. Collectively, these results define multiple chemotypes for further development and highlight novel molecular targets within nsP4 for CHIKV inhibition. IMPORTANCE Chikungunya virus is a mosquito-borne pathogen that has caused millions of human infections worldwide, producing severe fever, rash, and long-lasting joint pain that can persist for months. Related viruses, such as Mayaro and Ross River viruses, also cause debilitating disease, yet no antiviral drugs are available to treat any infection caused by this family of viruses. In this study, we developed a high-throughput assay that allowed us to rapidly identify compounds capable of blocking chikungunya virus replication. We discovered new hit compounds that inhibit virus growth. Our results suggest that the two most promising hit candidates target the viral nsP4 polymerase. By identifying these novel inhibitors and characterizing both their mechanisms of action and resistance profiles, we have established the groundwork for future efforts to develop much-needed therapies against chikungunya virus and related pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chikungunya virusAntiviral AgentsRNA-Dependent RNA PolymeraseEnzyme InhibitorsViral Nonstructural ProteinsHumansVirus ReplicationAnimalsHigh-Throughput Screening AssaysDrug Resistance, ViralMolecular Docking SimulationChikungunya FeverCell Line

Stichwörter der Autor:innen

antiviralchikungunyansP4 inhibitor

Substanzen

Antiviral AgentsRNA-Dependent RNA PolymeraseEnzyme InhibitorsViral Nonstructural Proteins

Autor:innen und Institutionen

  • Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Center for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
  • Institute of Bioengineering, University of Tartu, Tartu, Estonia.
  • Virology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Department of Chemistry, Emory University, Atlanta, Georgia, USA.

ORCID-Profile: Peiqi Yin, Dennis Liotta, Andres Merits, Alexander L Greninger, Richard K Plemper, Margaret Kielian, Robert M Cox

Förderung

  • NIAID NIH HHS

Zitieren

APA

Yin, P., Boyce, R., Wang, S., Sirrine, M., Leach, A., Chu, D., Vyshenska, D., Sahin, Z., Wong, J., Moore, T., Lewis, D. S. M., Pelly, S. C., Liotta, D., Merits, A., Greninger, A. L., Plemper, R. K., Kielian, M., & Cox, R. M. (2026). Identification and characterization of novel chikungunya virus polymerase inhibitors. Journal of Virology, 100(6). https://doi.org/10.1128/jvi.00305-26

Vancouver

Yin P, Boyce R, Wang S, Sirrine M, Leach A, Chu D, et al. Identification and characterization of novel chikungunya virus polymerase inhibitors. Journal of Virology. 2026;100(6). doi:10.1128/jvi.00305-26

BibTeX
@article{Yin2026,
  author = {Yin, Peiqi and Boyce, Ryan and Wang, Sainan and Sirrine, Michael and Leach, Alexander and Chu, Dillon and Vyshenska, Dariia and Sahin, Zafer and Wong, Jenny and Moore, Tahirah and Lewis, Devin Shane M and Pelly, Stephen C and Liotta, Dennis and Merits, Andres and Greninger, Alexander L and Plemper, Richard K and Kielian, Margaret and Cox, Robert M},
  title = {Identification and characterization of novel chikungunya virus polymerase inhibitors},
  journal = {Journal of Virology},
  year = {2026},
  volume = {100},
  number = {6},
  doi = {10.1128/jvi.00305-26}
}
Kostenlos starten →